{
    "ticker": "HSTO",
    "name": "HistoGeneX, Inc.",
    "description": "HistoGeneX, Inc. is a leading global provider of specialized laboratory services dedicated to advancing precision medicine through innovative pathology and diagnostic solutions. Founded in 2012, HistoGeneX focuses on delivering high-quality, comprehensive testing services that empower healthcare providers and their patients. The company offers a wide range of services, including histopathology, immunohistochemistry, and molecular diagnostics, all designed to support the development of targeted therapies in oncology and other disease areas. HistoGeneX is committed to enhancing patient outcomes by providing accurate and timely diagnostic information that aids in treatment decision-making. With state-of-the-art technology and a team of experienced professionals, the company is at the forefront of transforming pathology services into a more effective and efficient practice. HistoGeneX collaborates with pharmaceutical companies and research organizations to support clinical trials and biomarker discovery, playing a critical role in the development of new therapies. The company\u2019s mission is to innovate and deliver the highest standard of laboratory services to improve the quality of care for patients worldwide.",
    "industry": [
        "Healthcare",
        "Biotechnology"
    ],
    "headquarters": "Antwerp, Belgium",
    "founded": "2012",
    "website": "https://www.histogenex.com",
    "ceo": "Dr. Joris De Meester",
    "social_media": {
        "twitter": "https://twitter.com/HistoGeneX",
        "linkedin": "https://www.linkedin.com/company/histogenex/"
    },
    "investor_relations": "https://www.histogenex.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. Joris De Meester",
            "position": "CEO"
        },
        {
            "name": "Dr. Anja De Boeck",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Diagnostic Services",
            "products": [
                "Histopathology",
                "Immunohistochemistry",
                "Molecular Diagnostics"
            ]
        },
        {
            "category": "Clinical Trial Support",
            "products": [
                "Biomarker Discovery",
                "Clinical Trial Testing"
            ]
        }
    ],
    "seo": {
        "meta_title": "HistoGeneX, Inc. | Advanced Pathology and Diagnostic Solutions",
        "meta_description": "Learn about HistoGeneX, Inc., a leader in precision medicine through innovative pathology and diagnostic services. Discover how HistoGeneX is transforming healthcare.",
        "keywords": [
            "HistoGeneX",
            "Pathology",
            "Diagnostics",
            "Precision Medicine",
            "Oncology",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What services does HistoGeneX provide?",
            "answer": "HistoGeneX provides specialized laboratory services including histopathology, immunohistochemistry, and molecular diagnostics."
        },
        {
            "question": "Who is the CEO of HistoGeneX?",
            "answer": "Dr. Joris De Meester is the CEO of HistoGeneX, Inc."
        },
        {
            "question": "Where is HistoGeneX headquartered?",
            "answer": "HistoGeneX is headquartered in Antwerp, Belgium."
        },
        {
            "question": "What is the mission of HistoGeneX?",
            "answer": "HistoGeneX aims to innovate and deliver high-quality laboratory services to improve patient care."
        },
        {
            "question": "When was HistoGeneX founded?",
            "answer": "HistoGeneX was founded in 2012."
        }
    ],
    "competitors": [
        "LH",
        "DGX",
        "HOLX"
    ],
    "related_stocks": [
        "ABT",
        "MDT",
        "SYK",
        "BDX"
    ]
}